Neratinib

證據等級: L5

預測適應症: 4 個

Neratinib: From HER2-Positive Breast Cancer to Progesterone-Receptor Positive Breast Cancer

One-Sentence Summary

Neratinib is an irreversible pan-HER (EGFR/HER1, HER2, HER4) tyrosine kinase inhibitor whose established use — per the pivotal ExteNET Phase 3 trial and other trials contained in this evidence pack — is HER2-positive breast cancer; note that the drug's "original indication" field is itself flagged as a data gap in this registry and needs manual verification. The TxGNN model predicts it may also be effective for progesterone-receptor (PR) positive breast cancer, with 5 clinical trials and 10 publications currently supporting this direction, though the evidence base remains at an early stage (L2).

Quick Overview

Item	Content
Original Indication	Not available in this registry (`original_indications` empty, `market_status` = 未上市/Not Marketed) — a flagged data gap; literature in this pack indicates the drug's established use is HER2-positive breast cancer
Predicted New Indication	Progesterone-Receptor Positive Breast Cancer
TxGNN Prediction Score	99.68%
Evidence Level	L2
Norway Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Neratinib is an irreversible pan-HER tyrosine kinase inhibitor that blocks signaling through EGFR/HER1, HER2, and HER4. Clinically it is best established in HER2-positive breast cancer, where it has demonstrated benefit both as extended adjuvant therapy after trastuzumab (ExteNET, PMID 26874901) and in combination regimens for metastatic disease. PR status itself is not neratinib's direct molecular target, but PR-positive disease frequently co-occurs with HER2 positivity (the "triple-positive," HR+/HER2+ subgroup), and there is a clear pharmacological rationale for combining neratinib with endocrine therapy (e.g., fulvestrant, aromatase inhibitors) in this population — HER2 pathway activation is a recognized mechanism of endocrine resistance, and blocking it with neratinib is intended to restore endocrine sensitivity.

Several trials in this evidence pack directly test this combination strategy in HR+/HER2+ disease (e.g., NCT04886531: neoadjuvant neratinib + aromatase inhibitor + trastuzumab in ER+/HER2+ cancer), supporting the biological plausibility of the TxGNN prediction.

Important caveat flagged in the underlying data: this evidence pack records original_indications as empty and Norway market_status as "Not Marketed" with 0 authorizations, which is inconsistent with neratinib's known regulatory history (e.g., FDA-approved as Nerlynx for HER2+ breast cancer). This discrepancy is explicitly noted by the analysis pipeline itself and should be manually verified against the source database before this candidate advances further.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT04901299	Phase 2	Withdrawn	0	Planned to evaluate neratinib + fulvestrant in previously treated HR+/HER2-negative metastatic breast cancer; withdrawn before enrollment, no data generated
NCT04886531	Phase 2	Recruiting	30	Pre-operative neratinib + aromatase inhibitor + trastuzumab in ER-positive, HER2-positive breast cancer; results pending
NCT06131424	N/A (retrospective)	Completed	1,151	Multicenter retrospective study of HER2-low prevalence, characteristics, and treatment patterns in HER2-negative metastatic breast cancer; not an interventional efficacy study
NCT04460430	Phase 2	Terminated	12	Neratinib targeting EGFR/ERBB2 in HR-positive/HER2-negative, HER2-enriched advanced/metastatic breast cancer; terminated early with limited enrollment
NCT05599334	N/A (retrospective)	Completed	111	Retrospective observational study of neratinib as extended adjuvant therapy in early-stage HER2-positive breast cancer under the European Early Access Program; descriptive data only

Literature Evidence

PMID	Year	Type	Journal	Key Findings
26874901	2016	RCT	Lancet Oncology	ExteNET: Phase 3 RCT showing 12 months of neratinib after trastuzumab-based adjuvant therapy improves outcomes in early-stage HER2-positive breast cancer
27406346	2016	RCT	New England Journal of Medicine	I-SPY 2 adaptive Phase 2 trial evaluating neratinib among other novel agents added to neoadjuvant chemotherapy in high-risk breast cancer
35640077	2022	Review	J Clin Oncol	ASCO guideline update on systemic therapy for advanced HER2-positive breast cancer
29784737	2018	Review	JNCCN	NCCN guideline update on breast cancer, covering endocrine and HER2-directed treatment algorithms
32139271	2020	Review	Clinical Breast Cancer	Expert roundtable on HER2-positive breast cancer treatment developments, including neratinib and lapatinib
33726508	2021	Review	Future Oncology	Current treatment trends in HR-positive/HER2-positive breast cancer, discussing neratinib-based combinations
24892840	2013	Review	Clin Adv Hematol Oncol	Overview integrating recent metastatic breast cancer data by receptor subtype
39153126	2024	Cohort	Breast Cancer Res Treat	Real-world patterns of adjuvant neratinib use and tolerability in HR+/HER2+ early-stage breast cancer; notes significant GI toxicity driving discontinuation
32782013	2020	Cohort	Breast Cancer Research	In silico analysis of ERBB2 mutation status as a prognostic/targetable marker in ER-positive, ERBB2 non-amplified lobular breast cancer
35251981	2022	Case Series	Frontiers in Oncology	Case report/literature review of durable response with pyrotinib + vinorelbine in HER2-positive breast cancer with leptomeningeal disease (indirect relevance)

Norway Market Information

Neratinib is not currently marketed in Norway — the evidence pack lists 0 product authorizations, so no license table can be produced.

Cytotoxicity

Neratinib is an antineoplastic agent (targeted small-molecule kinase inhibitor used in breast cancer), so this section applies.

Item	Content
Cytotoxicity Classification	Targeted therapy — irreversible pan-HER (EGFR/HER2/HER4) tyrosine kinase inhibitor; not a conventional cytotoxic chemotherapy agent
Myelosuppression Risk	Not directly reported in this evidence pack; real-world literature (PMID 39153126) indicates the dominant treatment-limiting toxicity is gastrointestinal (diarrhea) rather than myelosuppression — formal hematologic toxicity data should be confirmed via the package insert
Emetogenicity Classification	Please refer to the package insert warnings and precautions
Monitoring Items	Liver function tests; close monitoring and proactive management of diarrhea/GI toxicity (per literature); CBC as standard oncology monitoring
Handling Protection	Please refer to the package insert warnings and precautions; oral formulation — institutional cytotoxic/hazardous drug handling protocols should be confirmed locally

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The PR-positive breast cancer prediction is biologically plausible given neratinib's established mechanism in HER2-driven, hormone receptor-positive disease, and is supported by ongoing/completed Phase 1–2 trials plus a strong precedent from the Phase 3 ExteNET trial in the broader HER2-positive population (L2 evidence). However, two blocking-level data gaps prevent a full go decision at this time.

To proceed, the following is needed:

Resolve the TFDA/local product label safety data gap (warnings, contraindications) — currently blocking any S1 safety evaluation
Confirm mechanism of action (MOA) directly via DrugBank rather than relying solely on trial-derived rationale
Manually verify the discrepancy between this dataset's "not marketed / no original indication" status and neratinib's known regulatory history (e.g., FDA approval as Nerlynx) before relying on this evidence pack for downstream decisions
Obtain results from the ongoing PR+/HR+-specific trial (NCT04886531) once available, since current PR+-specific trial evidence has no completed readouts
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.